Cholera disease
Conditions
Interventions
The Vaccine under study formulated at the Finlay Institute, is a lyophilized live oral vaccine, composed by the attenuated strain 638 V. cholerae from the serogroup O1, the biotype El Tor and the sero
Administration, Oral
Placebos
Sponsors
Finlay Institute
(CNIC) (Cuban National Center for Scientific Researches).
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1-Presumed-healthy adult male and female volunteers, between 18 to 40 years of age. 2-Written informed consent obtained from the subjects.
Exclusion criteria
Exclusion criteria: 1-Clinical manifestation of immunodeficiency. 2-Acute or chronic diseases adverted by volunteer during clinical examination or detected by mean of laboratory test, including bronchial asthma, cancer, neurological diseases, cardiovascular diseases and convulsions. 3-Previous history of immunization with cholera vaccines. 4-Previous cholera infections adverted by volunteers on the last 3 years. 5-History of acute diarrheas 30 days before the beginning of the trial, or chronic diarrheas. 6-Stool positive cultures for V. cholerae. 7-Optical density two times higher than the mean of optical densities of the 3 negative serum in each ELISA assay for IgG cholera antitoxin serum antibodies, in a 1:200 serum dilution, (O.D. serum sample 1:200 > 2 x mean of negatives controls). Otherwise the presence of vibriocidal antibodies titer = 1280 seven days before immunization. 8-Axilary temperature >= 37.5 °C at the very moment of vaccine/placebo administration. 9-Administration of antibiotics, antimalaric drugs, immunoglobulins or any blood products within 30 days preceding the treatment. 10-Subject under antiretroviral treatment. 11-Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs prior to the treatment. Inhaled and topical steroids are allowed. 12-Administration of a vaccine not foreseen by the study protocol 30 days before the treatment. 13-Do not approve a written examination in order to ensure the volunteers understanding related to the study and others elemental knowledge about cholera. 14-History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. 15-Pregnancy woman or breast-feeding. 16-Alcoholism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objectives: 1-To assess safety of 10E8-10E9 CFU single dose of 638 V. chorelae O1 El Tor Ogawa, a lyophilized live attenuated vaccine. 2-To assess reactogenicity during 14 days after application of vaccine or placebo. 3-To assess the vibriocidal antibody response against Ogawa serotype on days 0, 14 and 21 after treatment. Primary endpoints: 1-Incidence and relationship to the vaccine and (or) placebo administration of any serious adverse event within 30 days after vaccination. 2-Incidence of any grade 3 adverse event within 14 days after vaccine and (or) placebo administration. 3-Incidence of any other expected adverse events taking place within 14 days after treatment. 4-Incidence, intensity and relationship to the vaccine and (or) placebo administration of unexpected adverse events within 30 days after vaccination. 5-Incidence of out of normality range values and with clinical significance of the clinical lab tests, 7 days after vaccine and (or) placebo administration. 6-The Geometrical Mean titers of vibriocidal antibodies before vaccination, and on days 14, and 21 after vaccination in both groups of study. 7-Seroconversion defined as a fourfold increase of the initial titer with respect to the days 14 and (or) 21 titers in both groups of study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives: 1-To identify and to quantify, the attenuated 638 strains V. cholerae O1 El Tor Ogawa, excreted by volunteers every each third day, during the next 30 days after immunization. 2-To assess the ribotype, the lack of ctxAB genes, the presence of the hap::celA allele and the expression of CelA and OmpU proteins in V. cholerae O1 biotype El Tor strains isolated from volunteers stools on days 3, 6, 9, 15 and 30 of the study. 3-To describe the quantitative variation of CD4 and CD8 lymphocytes subpopulations and HIV viremia in volunteers, after treatment. Secondary endpoints: 1-To describe by mean of a survival analysis the dynamic of excretion, defining the event of interest as the occurrence of the third consecutive stool cultures negative of the attenuated 638 V. cholerae O1 El Tor Ogawa strain. 2-To calculate percentage of volunteers who shed the attenuated 638 strain V. cholerae O1 El Tor Ogawa every each 3 days during the next 30 days after vaccine feeding or until the occurrence of 3 consecutive stool negative cultures for 638 strain in both groups of study. 3-Percentage of V. cholerae O1 El Tor strains isolated from stools of volunteers on days 3, 6, 9, 15 and 30, which match with the 638 vaccine strain in the ribotype, the lack of ctxAB genes, the presence of the hap::celA allele, the expression of CelA and the lack of the expression of the OmpU proteins. 4-The mean, range and standard deviation to describe the variation of CD4 and CD8 lymphocytes subpopulations and HIV viremia in positive HIV volunteers on days 7, 14 and 21 after vaccination, as well as to describe the variation of CD4 and CD8 lymphocytes subpopulations using non-parametric test. | — |
Countries
Mozambique
Contacts
Public ContactHilda Garcia Sanchez
Finlay Institute
Outcome results
None listed